|
Synonyms: GS-5745 | GS5745
Compound class:
Antibody
Comment: Gilead Sciences designed andecaliximab (GS-5745), a humanized anti-MMP9 monoclonal antibody, for potential to treat solid tumours and inflammatory disorders [1-2]. GS-5745 inhibits MMP-9 activity by a combination of blocking proenzyme (zymogen) conversion to active enzyme, and allosterically inhibiting active MMP-9 catalytic activity [1].
Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
| Immunopharmacology Comments |
| Having initiated Phase 2 clinical trials in ulcerative colitis, Crohn's disease and rheumatoid arthritis, development of andecaliximab for inflammatory diseases appears to have been discontinued and all clinical trials terminated. |
| Immunopharmacology Disease | |||
| Disease | X-Refs | Comment | References |
| Chronic obstructive pulmonary disease |
Disease Ontology:
DOID:3083 |
Phase 1 study in COPD (NCT02077465) has been completed. | |
| Rheumatoid arthritis |
Disease Ontology:
DOID:7148 OMIM: 180300 |
Phase 2 clinical trial in RA patients has been terminated (see NCT02862574). | |
